Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials

被引：36

作者：

Connor, Donald J. ^{[1
]}

Sabbagh, Marwan N. ^{[1
]}

Cummings, Jeffery L. ^{[2
]}

机构：

[1] Sun Hlth Res Inst, Cleo Roberts Ctr Clin Res, Sun City, AZ USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

来源：

ALZHEIMERS & DEMENTIA | 2008年 / 4卷 / 06期

关键词：

Neuropsychiatric Inventory; NPI; Dementia; Alzheimer's; Clinical trial; Administration; Procedure;

D O I：

10.1016/j.jalz.2008.09.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: The Neuropsychiatric Inventory (NPI) is commonly used in dementia trials to quantify and qualitate changes in psychiatric symptoms. Methods: A questionnaire was administered to clinical trial raters to assess whether they were being trained to administer and score the NPI differently between clinical trial protocols. Results: Responses to the Survey indicated that there are differences between clinical trials protocols in how the instrument is administered and scored. Discussion: Clarification of administration and scoring rules are provided, including the behavioral sampling period, whether premorbid characteristics are considered. and what behaviors are considered in rating frequency, severity, and caregiver distress. (C) 2008 The Alzheimer's Association. All rights reserved.

引用

页码：390 / 394

页数：5

共 7 条

[1]

Barcia D, 1999, ACTAS ESP PSIQUIATRI, V27, P185

[2] The neuropsychiatric inventory: Assessing psychopathology in dementia patients [J].

Cummings, JL .

NEUROLOGY, 1997, 48 (05) :S10-S16

[3] THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].

CUMMINGS, JL ;

MEGA, M ;

GRAY, K ;

ROSENBERGTHOMPSON, S ;

CARUSI, DA ;

GORNBEIN, J .

NEUROLOGY, 1994, 44 (12) :2308-2314

[4] Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease [J].

Kaufer, D .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1998, 9 :8-14

[5] Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory caregiver distress scale [J].

Kaufer, DI ;

Cummings, JL ;

Christine, D ;

Bray, T ;

Castellon, S ;

Masterman, D ;

MacMillan, A ;

Ketchel, P ;

DeKosky, ST .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1998, 46 (02) :210-215

[6] Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: A placebo-controlled pilot study [J].

Mahlberg, Richard ;

Walther, Sebastian ;

Eichmann, Uta ;

Tracik, Ferenc ;

Kunz, Dieter .

ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2007, 45 (01) :19-26

[7] A 5-month, randomized, placebo-controlled trial of galantamine in AD [J].

Tariot, PN ;

Solomon, PR ;

Morris, JC ;

Kershaw, P ;

Lilienfeld, S ;

Ding, C .

NEUROLOGY, 2000, 54 (12) :2269-2276

← 1 →